

SynCoreBio®



杏國新藥股份有限公司
SynCore Biotechnology Co., Ltd.

2026 Investor Conference

17th August 2026 | Taipei

■ ■ Hui-Hung Wang
General Manager
SynCore Biotechnology



Disclaimer

The material in this presentation has been prepared by SynCore Biotechnology Co., Ltd as of the date of this presentation. While due care has been used to prepare this forecast information, actual results may vary in a materially positive or negative manner. Readers are cautioned not to place undue reliance on these forward looking statements. SynCore does not undertake any obligation to publicly release the result of any revisions to these forward looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. Unless otherwise specified, all information is based on the third quarter ending on August 3rd, 2026. Any unauthorized copying, alteration, distribution, transmission, performance, display or other use of this material is prohibited.

Operational Strategy

1.

Expansion of sales & marketing team

- ▶ Prioritize sales and launched products
- ▶ Focus in sales and marketing of nutraceuticals and in-licensed drugs

2.

New Formulation R&D

- ▶ Actively seeking partnerships for new drug formulations (lyophilized)
- ▶ License-out to drive operational growth

Nutraceuticals

杏國精準機能系列

專業 · 創新 · 尊重生命
Expertise Innovation Respect of Life



Nutraceutical Portfolio

Functional Health

Targeting:

▶ Sleep

▶ Digestion

▶ Eyes

▶ Lungs

Healthy Ageing

Targeting:

▶ Nutrition

▶ Joint care

CysLute® EX capsules



An innovative use of the herbal extract of
Cistache Tubulosa (Acteoside)
Patented ingredient



Dual Formulation for enhanced stability and absorption:

- Combines targeted protection and nourishing care
- Features a “moisture- retention” golden pyramid formula
- Over 70% of users reported a noticeable difference after use

CysLute® EX capsules

Supports healthy vision:

- Presented at the 2021 BIO Asia-Taiwan Exhibition, product launched in 2021
- 2021 Gold Medal International Warsaw Invention Show/ America's Science and Invention Expo
- Patent in Taiwan: TWI830221B (formulation to support eye comfort and hydration)



DreamPeptide Capsules



*Vegan-friendly



Protygold



2025 International
Innovation and
Invention Competition

Patented sleep-enhancing ingredient: walnut peptides

- Recognized by 5 prestigious international invention awards
- Supported by multiple peer-reviewed publications, demonstrating improved sleep quality



All美國達文西
發明金獎
USA



烏克蘭國際
發明金獎
Ukraine



波蘭國際發明
創新金獎
Poland



WiC韓國
發明金獎
South Korea



馬來西亞
發明獎
Malaysia

Dual pathway for sleep regulation support

- Enriched with Vitamin B6 to support nervous system health
- Includes Tryptophan – an amino acid precursor to the “happy hormone” serotonin and stabilizes the body’s circadian balance

PoriPeptide Capsules



Protygold



2025 International
Innovation and
Invention Competition

Dual patented ingredients: Poria Extract and walnut peptide

- An exclusive formula designed to support natural, effortless breathing in polluted environments
- Backed by published scientific studies indicating potential to enhance breathing quality



- Lungwort extract - to support clear breathing
- Iron – a nutrient that plays an important role in oxygen transport and absorption
- Niacin – to support the maintenance of mucosal health

*Vegan-friendly

Polysaccharide & Enzyme Sachets






Cistanche tubulosa polysaccharides

- Backed by published scientific literature for its support in promoting healthy intestinal movement
- Bridging traditional herbal knowledge with modern science
- Helps improve gut microbiome



2025 International
Innovation and
Invention Competition




Over 95% of users reported noticeable effect in bowel movement

- Formulated with bromelain and a variety of dietary fibers
- Helps soften stool

Cellular and Molecular Biochemistry R&D

Strategic Focus	Key Initiatives
Product development and pipeline expansion	▶ Animal-derived FECV-01 product development (Cosmetics raw materials/skincare applications) ▶ Other diagnostic products

FECV-01 Development Progress



Application Number: **2025-13706**


Submitted By: Industrial Technology Research Institute

Manufactured By: SynCore Biotechnology Co., Ltd.

Tradename: SynExo

If a tradename is not provided on the application, or the tradename field on the application is marked proprietary, the INCI name is published without a tradename or reference to the manufacturer.

If the assigned INCI name is a mixture, the components are listed in the table below in descending order of predominance.



1. Building on our fish-derived cellular research platform, SynCore has developed proprietary fish-derived extracellular vesicles. In February 2026, FECV-01 obtained its International Nomenclature of Cosmetic Ingredients (INCI) name, enabling its compliant use as a cosmetic ingredient.
2. We plan to collaborate with aesthetic medicine specialists to further evaluate the clinical efficacy and potential applications of FECV-01.

CMC

EndoTAG[®] Platform Technology

- Proprietary EndoTAG[®]-1 technology for targeted drug delivery
- Improve formulation using CT4006 clinical trial data
- Continue development in dosage form reformulation
- Liposomal reformulation and repurposing

SynCore's Outlook

- 1. Driving clinical and commercialization growth as operational strategy**
- 2. Expansion and diversification of product portfolio across three key areas: Oncology Therapeutics, Nutraceuticals, Functional Raw Materials in cosmetics, with a focus on securing regulatory approvals**
- 3. EndoTAG[®] platform technology reformulation**
- 4. Expansion of Business Development: Pursue strategic partnerships and collaboration opportunities**

SynCore*Bio*®



+886-2-27603688



BD@syncorebio.com Finance@syncorebio.com



<http://www.syncorebio.com/en/>



4F, No.69, Dongxing Road, Xinyi District, Taipei, 11070 Taiwan



SynCore Biotechnology Co., Ltd.

professional, INNOVATION,
and respect of life

